Table 2.

Phase III trials with PARP inhibitors.

Type of Tumor	Author	Principal Endpoint	Treatment	Benefit	OS Benefit	Target	Sub-Population
Breast Cancer
Localized disease	Tutt et al., 2021 [80]	DFS	Local treatment and neoadjuvant or adjuvant chemotherapy. Olaparib vs. placebo.	Yes	NS	gBRCA1/2	71.3% BRCA1 28.3% BRCA2
Pre-treated M1 or unresectable	Diéras 2020 [93]	PFS	Carbo, pacli ± veliparib	Yes	NS	gBRCA1/2	-
	Litton 2018 [78]	PFS	Chemo 1 vs. Talazoparib	Yes	NS	gBRCA1/2	-
	Robson 2017 [79]	PFS	Chemo 1 vs. olaparib	Yes	NS	gBRCA1/2	-
	O’Shaughnessy 2014 [94]	PFS and OS	Carbo, gem ± iniparib	Yes	Yes	Triple negative
Ovarian Cancer
1st line maintenance	Coleman 2019 [95]	PFS	Carbo, pacli ± veliparib	Yes	NR	Platinum sensitive	30% BRCA, 60% HRD
	Gonzalez-Martin 2019 [76]	PFS	Niraparib vs. placebo	Yes	NS 2	Platinum sensitive	30% BRCA 51% HRD
	Ray-Coquard 2019 [76]	PFS	Olaparib + Bevacizumab	Yes	NR	Platinum sensitive	30% BRCA 50% HRD
	Moore 2018 [74]	PFS	Olaparib vs. placebo	Yes	NS 2	BRCA1/2 3
Platinum sensitive recurrence	Coleman 2017 [96]	PFS	Rucaparib vs. placebo	Yes	NS 2	Platinum sensitive	35% BRCA 60% HRD
	Pujade-Lauraine 2017 [97]	PFS	Olaparib vs. placebo	Yes	NS	gBRCA1/2
	Mirza 2016 [72]	PFS	Niraparib vs. placebo	Yes	NS	Platinum sensitive	BRCA and non-BRCA cohorts
Pancreatic Cancer
1st line maintenance	Golan 2019 [61]	PFS	Olaparib vs. placebo	Yes	NS 2	gBRCA1/2 + platinum sensitive
Prostate Cancer
Pre-treated M1 CRPC	De Bono 2020 [83]	PFS in cohort A	Olaparib vs. AA/enza	Yes	NS	Somatic HRD by NGS 15 genes multi-panel	Cohort A: BRCA + ATM Cohort B: non-BRCA/ATM

¹ Physician’s choice chemotherapy. ² Immature data published. ³ Only two patients had somatic BRCA1/2 mutation.